R&D110

R&D110 is a 6-month long-acting injectable (LAI) formulation being developed by Bostal Drug Delivery for the treatment of schizophrenia. Developed via the 505(b)(2) regulatory pathway, the product aims to provide a half-year therapeutic effect from a single dose, significantly extending the dosing interval compared to existing one- or two-month formulations. While the specific active pharmaceutical ingredient has not been disclosed, the drug is part of Bostal's pipeline of depot antipsychotics designed to improve long-term treatment adherence and stabilize plasma drug levels. As of 2024, the candidate is in early-stage development, with Phase 1 clinical milestones projected for 2027.